BBIO News and Press, BridgeBio Pharma Inc. From 01/03/24

The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRAS G12C that binds to the Switch II pocket in both the ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-18 05:34:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq . However, the small-to-mid cap index appears to be closing the gap. After a st...

- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia - The U.S. Food and Drug Administration (FDA) and European Union (EU) European Med...

2023-12-12 20:24:54 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased slightly to $24.64B, with 80 holdings. The largest positions in the portfolio are Visa, Workday, Amazon.com, United Parcel Service, and Danaher Corp. New stakes include Block Inc., Freep...

2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares  ( HBANL ) +3% . Genmab  ( GMAB ) +3% . Losers: Fluence En...

2023-12-05 12:04:02 ET More on BridgeBio Pharma BridgeBio Pharma: Taking Some Profits BridgeBio: Bets Acoramidis As The Pfizer Spoiler BridgeBio draws Buy rating at Cantor citing 100% upside BridgeBio Pharma to issue 9.2M shares through PIPE financing ...

- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p<0.0001), on the primary endpoint (a hierarchical analysis prioritizing in order all-cause mortality (ACM), then frequency of...

2023-12-04 16:44:43 ET Summary BridgeBio Pharma, Inc. has seen its stock more than double since May, triggered by positive trial results for its late-stage asset Acoramidis. The company has a unique business model focused on developing therapies for individual diseases and buildin...

2023-11-24 02:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...